Jason A. Keyes

CIK: 0001678152

Transaction Breakdown

Open Market Buys (P)1 (5.3%)

High conviction signal

Open Market Sales (S)3 (15.8%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)10 (52.6%)

Compensation grants

Other (G, F, J, C, D, …)5 (26.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

BLSM

BlossomHill Therapeutics, Inc.

Officer

ACTU

ACTUATE THERAPEUTICS, INC.

Director

Equillium, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (19 total)

BLSM
BlossomHill Therapeutics, Inc.
Aug 10, 2026
Purchase(P)
Direct
700 shares at avg. $16.00$11K
BLSM
BlossomHill Therapeutics, Inc.
Aug 6, 2026
Award(A)
Employee Stock Option (Right to Buy)
Direct
56.7K shares-
ACTU
ACTUATE THERAPEUTICS, INC.
May 21, 2026
Award(A)
Stock Options
Direct
15K shares-
ACTU
ACTUATE THERAPEUTICS, INC.
May 22, 2025
Award(A)
Stock Options
Direct
15K shares-
EQ
Equillium, Inc.
Feb 14, 2025
Disposition(D)
Employee Stock Option (right to buy)
Direct
175K shares-
EQ
Equillium, Inc.
Feb 14, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
100K shares-
EQ
Equillium, Inc.
Feb 14, 2025
Disposition(D)
Employee Stock Option (right to buy)
Direct
100K shares-
EQ
Equillium, Inc.
Feb 14, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
125K shares-
EQ
Equillium, Inc.
Feb 14, 2025
Disposition(D)
Employee Stock Option (right to buy)
Direct
125K shares-
EQ
Equillium, Inc.
Feb 14, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
175K shares-
EQ
Equillium, Inc.
Feb 14, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
70K shares-
EQ
Equillium, Inc.
Feb 14, 2025
Disposition(D)
Employee Stock Option (right to buy)
Direct
70K shares-
EQ
Equillium, Inc.
Feb 14, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
90K shares-
EQ
Equillium, Inc.
Feb 14, 2025
Disposition(D)
Employee Stock Option (right to buy)
Direct
90K shares-
EQ
Equillium, Inc.
Jan 23, 2025
Sale(S)
Indirect
10K shares at avg. $0.65$7K
EQ
Equillium, Inc.
Jan 2, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
175K shares-
EQ
Equillium, Inc.
Dec 10, 2024
Award(A)
Direct
15K shares at avg. $0.54$8K
EQ
Equillium, Inc.
Nov 14, 2024
Sale(S)
Indirect
10K shares at avg. $0.70$7K
EQ
Equillium, Inc.
Sep 26, 2024
Sale(S)
Indirect
10K shares at avg. $0.81$8K

		Type	Shares	Price		Ownership
Aug 10, 2026	BLSM BlossomHill Therapeutics, Inc.	Purchase(P)	700	$16.00	$11,200	Direct
Aug 6, 2026	BLSM BlossomHill Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	56,746	-	-	Direct
May 21, 2026	ACTU ACTUATE THERAPEUTICS, INC.	Award(A) Stock Options	15,000	-	-	Direct
May 22, 2025	ACTU ACTUATE THERAPEUTICS, INC.	Award(A) Stock Options	15,000	-	-	Direct
Feb 14, 2025	EQ Equillium, Inc.	Disposition(D) Employee Stock Option (right to buy)	175,000	-	-	Direct
Feb 14, 2025	EQ Equillium, Inc.	Award(A) Employee Stock Option (right to buy)	100,000	-	-	Direct
Feb 14, 2025	EQ Equillium, Inc.	Disposition(D) Employee Stock Option (right to buy)	100,000	-	-	Direct
Feb 14, 2025	EQ Equillium, Inc.	Award(A) Employee Stock Option (right to buy)	125,000	-	-	Direct
Feb 14, 2025	EQ Equillium, Inc.	Disposition(D) Employee Stock Option (right to buy)	125,000	-	-	Direct
Feb 14, 2025	EQ Equillium, Inc.	Award(A) Employee Stock Option (right to buy)	175,000	-	-	Direct
Feb 14, 2025	EQ Equillium, Inc.	Award(A) Employee Stock Option (right to buy)	70,000	-	-	Direct
Feb 14, 2025	EQ Equillium, Inc.	Disposition(D) Employee Stock Option (right to buy)	70,000	-	-	Direct
Feb 14, 2025	EQ Equillium, Inc.	Award(A) Employee Stock Option (right to buy)	90,000	-	-	Direct
Feb 14, 2025	EQ Equillium, Inc.	Disposition(D) Employee Stock Option (right to buy)	90,000	-	-	Direct
Jan 23, 2025	EQ Equillium, Inc.	Sale(S)	10,000	$0.65	$6,500	Indirect
Jan 2, 2025	EQ Equillium, Inc.	Award(A) Employee Stock Option (right to buy)	175,000	-	-	Direct
Dec 10, 2024	EQ Equillium, Inc.	Award(A)	15,000	$0.54	$8,100	Direct
Nov 14, 2024	EQ Equillium, Inc.	Sale(S)	10,000	$0.70	$7,000	Indirect
Sep 26, 2024	EQ Equillium, Inc.	Sale(S)	10,000	$0.81	$8,100	Indirect

1-19 of 19 transactions

About Keyes Jason A

Keyes Jason A (SEC CIK 0001678152) files insider reports with the SEC as Chief Financial Officer of BlossomHill Therapeutics, Inc. (BLSM), Director of ACTUATE THERAPEUTICS, INC. (ACTU) and Chief Financial Officer of Equillium, Inc. (EQ).

Signal8 holds 9 ownership filings by Keyes Jason A (1 Form 3, 8 Form 4), filed between Sep 27, 2024 and Aug 10, 2026. Those filings report 19 transactions, from Sep 26, 2024 to Aug 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Keyes Jason A's filings is in SAN DIEGO, CA.

Recent filings by Keyes Jason A

Aug 10, 2026: Open-market purchase of BLSM shares (Form 4, code P).
Aug 6, 2026: Grant or award of BLSM derivative securities (Form 4, code A).
May 21, 2026: Grant or award of ACTU derivative securities (Form 4, code A).
May 22, 2025: Grant or award of ACTU derivative securities (Form 4, code A).
Feb 14, 2025: Disposition to issuer transaction of EQ derivative securities (Form 4, code D).

Other insiders filing for BlossomHill Therapeutics, Inc. (BLSM)

GORDON CARL L, Director
ORBIMED ADVISORS LLC, Director
Schmid John P., Director
Chen Bihua, Director
Agrawal Sundeep, Director
Liptak Vincent Paul, General Counsel

How to read Form 4 transaction codes